Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) EBT (2020 - 2025)

BioAtla (BCAB) has disclosed EBT for 6 consecutive years, with -$9.2 million as the latest value for Q4 2025.

  • For Q4 2025, EBT rose 41.48% year-over-year to -$9.2 million; the TTM value through Dec 2025 reached -$58.5 million, up 17.16%, while the annual FY2025 figure was -$58.5 million, 17.16% up from the prior year.
  • EBT hit -$9.2 million in Q4 2025 for BioAtla, up from -$13.7 million in the prior quarter.
  • Across five years, EBT topped out at -$9.2 million in Q4 2025 and bottomed at -$35.7 million in Q2 2023.
  • Average EBT over 5 years is -$22.8 million, with a median of -$23.5 million recorded in 2021.
  • Year-over-year, EBT crashed 1508.0% in 2021 and then skyrocketed 68.22% in 2024.
  • BioAtla's EBT stood at -$23.4 million in 2021, then decreased by 17.62% to -$27.5 million in 2022, then rose by 2.24% to -$26.9 million in 2023, then soared by 41.67% to -$15.7 million in 2024, then surged by 41.48% to -$9.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$9.2 million, -$13.7 million, and -$18.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.